Introduction
Results
Hepatitis B serologic survey
No. of participants tested*/total number of recruited participants (%)
| ||||
---|---|---|---|---|
Born after launch of HBB immunization program
|
Born before launch of HBB immunization program
| |||
Division
|
Children (6 mos. to <5 yrs. old)
|
Adolescents (16 to 20 yrs. old)
|
Adults (21 to 49 yrs. old)
|
Total
|
Central | 193/204 (94.6%) | 50/50 (100%) | 149/150 (99.3%) | 392/404 (97.0%) |
Western | 168/175 (96.0%) | 49/50 (98.0%) | 148/150 (98.7%) | 365/375 (97.6%) |
Northern | 71/71 (100%) | 25/25 (100%) | 73/75 (97.3%) | 169/171 (98.85) |
Total | 432/450 (96.0%) | 124/125 (99.2%) | 370/375 (98.7%) | 926/950 (97.5%) |
Age group
|
HBsAg
|
anti-HBs
|
anti-HBc
| ||||||
---|---|---|---|---|---|---|---|---|---|
No. positive/no.tested
|
%
|
95%CI
|
No. positive/no.tested
|
%
|
95%CI
|
No. positive/no.tested
|
%
|
95%CI
| |
Children | |||||||||
6 mos – <5 yrs | 0/432 | 0.0% | 0.0-1.1 | 424/432 | 98.1% | 96.2-99.1 | 0/432 | 0.0% | 0.0-1.1 |
Adolescent | |||||||||
16-20 yrs | 7/124 | 5.6% | 2.3-11.3 | 22/124 | 17.7% | 11.5-25.6 | 11/124 | 8.9% | 4.5-15.3 |
Adult (n = 370) | |||||||||
21-29 yrs | 2/124 | 1.6% | 0.2-5.7 | 34/124 | 27.4% | 19.8-36.2 | 22/124 | 17.7% | 11.5-25.6 |
30-39 yrs | 5/123 | 4.1% | 1.3-9.2 | 39/123 | 31.7% | 23.6-40.7 | 27/123 | 22.0% | 15.0-30.3 |
40-49 yrs | 5/123 | 4.1% | 1.3-9.2 | 34/123 | 27.6% | 20.0-36.4 | 26/123 | 21.1% | 14.3-29.4 |
Total | 19/926 | 2.0% | 1.3-3.2 | 553/926 | 59.7% | 56.5-62.9 | 86/926 | 9.2% | 7.5-11.3 |
Serologic markers
|
Children(6 mos- < 5 yrs)
|
Adolescents(16–20 yrs)
|
Adults(21–49 yrs)
|
Adolescents + Adults(16–49 yrs)
| ||||
---|---|---|---|---|---|---|---|---|
Combination | HBsAg | anti-HBc | anti-HBs | |||||
1 | - | - | - | 8* | 94 | 232 | 326 | susceptible, never infected |
2 | + | - | - | 0 | 4 | 4 | 8 | early acute infection |
3 | + | + | - | 0 | 3 | 6 | 9 | acute or chronic infection |
4 | - | + | - | 0 | 1 | 21 | 22 | past infection or false positive (i.e. susceptible), or “low level” chronic infection |
5 | - | + | + | 0 | 7 | 46 | 53 | Past infection; recovered and immune |
6 | + | - | + | 0 | 0 | 0 | 0 | ------- |
7 | - | - | + | 424 | 15 | 59 | 74 | Immune due to hepatitis B vaccine |
8 | + | + | + | 0 | 0 | 2 | 2 | Acute or chronic infection |
Total | 432 | 124 | 370 | 494 |
HBsAg
|
anti-HBs
|
anti-HBc
| |||||||
---|---|---|---|---|---|---|---|---|---|
No. positive/no.tested
|
%
|
95%CI
|
No. positive/no.tested
|
%
|
95%CI
|
No. positive/no.tested
|
%
|
95%CI
| |
21-49 years
| 12/370 | 3.2% | 1.8-5.8 | 107/370 | 28.9% | 24.4-33.9 | 75/370 | 20.3% | 16.4-24.8 |
Division
| |||||||||
Central | 10/149 | 6.7% | 3.3-12.0 | 50/149 | 33.6% | 26.0-41.7 | 35/149 | 23.5% | 16.9-31.1 |
Western | 1/148 | 0.7% | 0.0-3.7 | 17/148 | 11.5% | 6.8-17.8% | 19/148 | 12.8% | 7.9-19.3 |
Northern | 1/73 | 1.4% | 0.0-7.4 | 40/73 | 54.8% | 42.7-66.5 | 21/73 | 28.8% | 18.8-40.6 |
Gender
| |||||||||
Male | 7/310 | 2.3% | 1.0-4.8 | 88/310 | 28.4% | 23.5-33.8 | 63/310 | 20.3% | 16.1-25.3 |
Female | 5/60 | 8.3% | 2.8-18.4 | 19/60 | 31.7% | 20.3-45.0 | 12/60 | 20.0% | 10.8-32.3 |
Ethnic group
| |||||||||
Fijian | 9/137 | 6.6% | 3.0-12.1 | 73/137 | 53.3% | 44.6-61.9 | 50/137 | 36.5% | 28.4-45.1 |
Indian | 1/204 | 0.5% | 0.0-2.7 | 20/204 | 9.8% | 6.1-14.7 | 15/204 | 7.4% | 4.2-11.8 |
Others | 2/29 | 6.9% | 0.8-22.8 | 14/29 | 48.3% | 29.4-67.5 | 10/29 | 34.5% | 17.9-54.3 |
Hepatitis B immunization coverage
Category
|
No. of children with the feature in each category/total no. of children (%)
| |||
---|---|---|---|---|
Central
|
Western
|
Northern
|
Total
| |
Coverage in terms of number of dose (s) received during hepatitis B immunization (total n = 439) | ||||
Three doses or more | 191/194 (98.5) | 173/173 (100.0) | 72/72 (100.0) | 436/439 (99.3) |
Only two doses | 3/194 (1.5) | 0/173 (0.0) | 0/72 (0.0) | 3/439 (0.7) |
Only one dose | 0/194 (0.0) | 0/173 (0.0) | 0/72 (0.0) | 0/439 (0.0) |
Timeliness of birth dose (total n = 439) | ||||
Within 2 days | 170/194 (87.6) | 156/173 (90.2) | 53/72 (73.6) | 379/439 (86.3) |
Day 3 – 10 | 16/194 (8.2) | 8/173 (4.6) | 17/72 (23.6) | 41/439 (9.3) |
Day 10 – 30 | 5/194 (2.6) | 5/173 (2.9) | 1/72 (1.4) | 11/439 (2.5) |
Never immunized | 3/194 (1.5) | 4/173 (2.3) | 1/72 (1.4) | 8/439 (1.8) |
Timeliness of completion of 3 doses of HBV in children < 2 years | ||||
(total n = 176) | ||||
On – schedule | 46/62 (74.2) | 50/79 (63.3) | 7/35 (20.0) | 103/176 (58.5) |
Delayed | 16/62 (25.8) | 29/79 (36.7) | 28/35 (80.0) | 73/176 (41.5) |
Discussion
Immunized children
|
Unimmunized adult
| |||
---|---|---|---|---|
1998
a
|
2008
|
1998
b
|
2009
c
| |
HBsAg positive | 2/285 (0.7%) | 0/432 (0.0%) | 19/290 (6.6%) | 12/370 (3.2%) |
anti-HBs positive | 217/282 (77.0%) | 424/432 (98.1%) | 168/290 (57.9%) | 107/370 (28.9%) |
anti-HBc positive | 15/281 (5.3%) | 0/432 (0.0%) | 195/290 (67.2%) | 75/370 (20.3%) |
Central
|
Western
|
Northern
|
Total
| |
---|---|---|---|---|
Birth dose | 67.4 (98.5) | 92.0 (97.7) | 89.3 (98.6) | 80.3 (98.2) |
Third dosea
| 76.3 (98.5) | 88.0 (100.0) | 83.6 (100.0) | 81.9 (99.3) |